Artin Terhakopian, MD
Psychiatry · Pueblo, CONPI 1962466110
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $650 and has fallen 57.4% since, to $277 in 2024. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$435
- Neurocrine Biosciences, Inc.$346
- Otsuka America Pharmaceutical, Inc.$206
- Alkermes, Inc.$204
- Takeda Pharmaceuticals U.S.A., Inc.$158
- Sunovion Pharmaceuticals Inc.$149
- plus $947 from 16 others
What the payments were for
- Food & beverage$2,39898%
- Education$492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,447 in reported general payments places this provider in the 90th percentile of 559 psychiatry providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $115,178 |
| VraylarCariprazine Hcl | 24 | $36,151 |
| Invega SustennaPaliperidone Palmitate | 12 | $32,164 |
| Abilify MaintenaAripiprazole | 12 | $26,135 |
| TrintellixVortioxetine Hydrobromide | 40 | $25,902 |
| DayvigoLemborexant | 37 | $12,357 |
| Asenapine Maleate | 37 | $9,205 |
| Paliperidone ErPaliperidone | 24 | $5,736 |
| Lurasidone Hcl | 41 | $3,866 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 36 | $3,178 |
| Duloxetine Hcl | 107 | $3,175 |
| Clozapine | 47 | $2,923 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 39 | $2,199 |
| Lamotrigine | 86 | $1,619 |
| Aripiprazole | 56 | $1,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $346 | $115,17815 claims |
| AbbVieVraylar | $435 | $36,15124 claims |
| Johnson & JohnsonInvega Sustenna | $73 | $32,16412 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $206 | $26,13512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $158 | $25,90240 claims |
| Eisai Inc.Dayvigo | $51 | $12,35737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Pueblo
- John HardyPueblo$828K
- John DequardoPueblo$17K
- Musharraf NizamiPueblo$6K
- Michael SaathoffPueblo$2K
- Larry SandersLittleton$760K
- Jeffrey RichmondDenver$424K
- Jennifer FrenchGlendale$115K
- Charles ParkLone Tree$89K
- Cynthia EppersonAurora$64K
- Brian WiseCentennial$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.